

ABSTRACT OF THE DISCLOSURE

dot 7
C

The invention relates to nucleic acid molecules which encode fusion proteins which contain as components at least one effector module, a processing module and a targeting module. The nucleic acid molecules according to the invention preferably also encode a modulator module and/or an affinity module. The invention furthermore relates to vectors containing these nucleic acid molecules, hosts transformed with the vectors according to the invention, fusion proteins encoded by nucleic acids according to the invention or produced by the hosts according to the invention as well as to medicaments containing the polypeptides or vectors according to the invention. These medicaments are particularly significant for the therapy of diseases associated with a pathological reproduction and/or increased activity of cell populations. A temporary, periodic and strong proliferation, infiltration and immune activity of cells of the immune system is found in autoimmune diseases and allergies, the specificity of these immune cells being due to their reaction to a particular antigen or allergen. These medicaments may also be advantageously used for treating tumors. The polypeptides and vectors described in the present invention may be used to develop medicaments and to test toxin activity-modulating factors. The invention thus also concerns corresponding processes, uses and kits. The modules, with the exception of the affinity and the targeting module, are preferably encoded by nucleic acids extracted or derived from the mistletoe lectin proprotein coding sequence.